This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review. Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner. Somatostatin analogues are considered first line therapy for unresectable carcinoids, whereas systemic chemotherapy is most appropriate for progression of disease.
You are here:
Pulmonary Neuroendocrine (Carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoid
Submitted by: Mark Ferguson
Source: Annals of Oncology
Keywords:
Author(s): M.E. Caplin, E. Baudin, P. Ferolla, P. Filosso, M. Garcia-Yuste, E. Lim, K. Oberg, G. Pelosi, A. Perren, R. Elisa Rossi, W.D. Travis, the ENETS consensus conference participants
